De novo patients with high-volume metastatic hormone-sensitive prostate cancer can benefit from the addition of docetaxel to triplet therapy: Network-analysis and systematic review.

Chin Med J (Engl)

Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.

Published: September 2024

Download full-text PDF	Source
http://dx.doi.org/10.1097/CM9.0000000000003311	DOI Listing

Publication Analysis

novo patients

patients high-volume

high-volume metastatic

metastatic hormone-sensitive

hormone-sensitive prostate

prostate cancer

cancer benefit

benefit addition

addition docetaxel

docetaxel triplet

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!